Latest Inhibikase Therapeutics Inc. Stories
ATLANTA, Aug. 16, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML). This proof-of-concept trial will be conducted in multiple sclerosis (MS)...
ATLANTA, May 17, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc. today announced the election Dr. Steven C. Gilman to the Board of Directors of Inhibikase Therapeutics, Inc. (Logo: http://photos.prnewswire.com/prnh/20110517/CL02791LOGO ) Dr. Steven Gilman joined Cubist Pharmaceuticals in 2008 and currently serves as the Cubist's Executive Vice President, Research & Development and Chief Scientific Officer. Before joining Cubist Pharmaceuticals, Dr. Gilman held several positions...
- Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
- Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
- Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
- A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.